CUVPOSA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cuvposa, and what generic alternatives are available?
Cuvposa is a drug marketed by Merz Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in CUVPOSA is glycopyrrolate. There are seventeen drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cuvposa
A generic version of CUVPOSA was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
Summary for CUVPOSA
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 97 |
| Patent Applications: | 3,746 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CUVPOSA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CUVPOSA |
| What excipients (inactive ingredients) are in CUVPOSA? | CUVPOSA excipients list |
| DailyMed Link: | CUVPOSA at DailyMed |
Paragraph IV (Patent) Challenges for CUVPOSA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| CUVPOSA | Oral Solution | glycopyrrolate | 1 mg/5 mL | 022571 | 1 | 2012-06-20 |
US Patents and Regulatory Information for CUVPOSA
CUVPOSA is protected by two US patents.
Patents protecting CUVPOSA
Method for increasing the bioavailability of glycopyrrolate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA)IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
Method for increasing the bioavailability of glycopyrrolate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA)IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merz Pharms | CUVPOSA | glycopyrrolate | SOLUTION;ORAL | 022571-001 | Jul 28, 2010 | AA | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Merz Pharms | CUVPOSA | glycopyrrolate | SOLUTION;ORAL | 022571-001 | Jul 28, 2010 | AA | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
